Back to resultsA Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Primary Purpose
Non-Squamous Non-Small Cell Lung Cancer
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Erlotinib
Onartuzumab (MetMab)
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Non-Squamous Non-Small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria:
- Adult participants, greater than or equal to (>/=) 18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Histologically or cytologically confirmed incurable Stage IIIb/IV NSCLC tumor
- Met diagnostic-positive status tested by immunohistochemistry (IHC)
- Results of endothelial growth factor receptor (EGFR)-activating mutation testing
- Radiographic evidence of disease
- Prior treatment with at least one platinum-based line of treatment (for stage IIIb/IV) and no more than one additional line of chemotherapy treatment; the last dose of chemotherapy must have been administered >/= 21 days prior to Day 1
- availability of tissue sample for diagnostic testing is required
Exclusion Criteria:
- More than 30 days of exposure to an investigational or marketed agent that can act by EGFR inhibition, or a known EGFR-related toxicity resulting in dose modifications (EGFR inhibitors including but not limited to gefitinib, erlotinib and cetuximab)
- Brain metastases or spinal cord compression not definitively treated with surgery and/or radiation, or previously treated central nervous system (CNS) metastases or spinal cord compression without evidence of stable disease for >/= 14 days
- History of another malignancy in the previous 3 years, unless cured by surgery alone and continuously disease free for at least 3 years; participants with prior history of non-invasive cancers are eligible
- Inadequate hematological, biochemical or organ function
- Significant history of cardiac disease
- Serious active infection at time of randomization or other serious underlying medical conditions that would impair the ability of the participant to receive protocol treatment
- Any inflammatory changes of the surface of the eye
- Clinically significant gastro-intestinal disease, including uncontrolled inflammatory gastro-intestinal diseases
- Pregnant or lactating women
- Positive for human immunodefinciency (HIV) infection
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Onartuzumab+Erlotinib
Placebo+Erlotinib
Arm Description
Participants will receive onartuzumab 15 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally once daily (QD) from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
Participants will receive onartuzumab matching placebo on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally QD from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
Outcomes
Primary Outcome Measures
Overall Survival
Secondary Outcome Measures
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) Scores
Onartuzumab Serum Concentrations
Percentage of Participants With Disease Progression or Death
Progression Free Survival (PFS)
Percentage of Participants with an Objective Response Assessed Using RECIST V 1.1
Full Information
NCT ID
NCT01456325
First Posted
October 18, 2011
Last Updated
November 1, 2016
Sponsor
Genentech, Inc.
Collaborators
Hoffmann-La Roche
1. Study Identification
Unique Protocol Identification Number
NCT01456325
Brief Title
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Official Title
A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
January 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Genentech, Inc.
Collaborators
Hoffmann-La Roche
4. Oversight
5. Study Description
Brief Summary
This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in participants with incurable non-small cell lung cancer identified to be Met diagnostic-positive. Participants will be randomized to receive either onartuzumab (MetMAb) or placebo in combination with erlotinib. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Squamous Non-Small Cell Lung Cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
494 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Onartuzumab+Erlotinib
Arm Type
Experimental
Arm Description
Participants will receive onartuzumab 15 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally once daily (QD) from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
Arm Title
Placebo+Erlotinib
Arm Type
Placebo Comparator
Arm Description
Participants will receive onartuzumab matching placebo on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally QD from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
Intervention Type
Drug
Intervention Name(s)
Erlotinib
Other Intervention Name(s)
Tarceva
Intervention Description
Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
Intervention Type
Drug
Intervention Name(s)
Onartuzumab (MetMab)
Other Intervention Name(s)
RO5490258
Intervention Description
Participants will receive onartuzumab 15 mg/kg IV infusion on Day 1 of every 3-week cycle.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
Primary Outcome Measure Information:
Title
Overall Survival
Time Frame
Randomization until death (up to approximately 18 months) (assessed at the treating physician's discretion using the local standard-of-care practice)
Secondary Outcome Measure Information:
Title
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) Scores
Time Frame
Screening, Day 1 of Cycles 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 (cycle length = 21 days), study drug discontinuation visit (up to approximately 18 months)
Title
Onartuzumab Serum Concentrations
Time Frame
1 hour pre-onartuzumab (Pr-O) infusion on Day 1 of Cycles 1, 2, and 4, 1 hour post-onartuzumab (Po-O) infusion on Day 1 of Cycle 1 (cycle length = 21 days and duration of infusion = 60 minutes), End of treatment (up to approximately 18 months)
Title
Percentage of Participants With Disease Progression or Death
Time Frame
Randomization until disease progression or death, whichever occurred first (up to approximately 18 months) (assessed at the treating physician's discretion using the local standard-of-care practice)
Title
Progression Free Survival (PFS)
Time Frame
Randomization until disease progression or death, whichever occurred first (up to approximately 18 months) (assessed at the treating physician's discretion using the local standard-of-care practice)
Title
Percentage of Participants with an Objective Response Assessed Using RECIST V 1.1
Time Frame
Randomization until disease progression or death, whichever occurred first (up to approximately 18 months) (assessed at the treating physician's discretion using the local standard-of-care practice)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult participants, greater than or equal to (>/=) 18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Histologically or cytologically confirmed incurable Stage IIIb/IV NSCLC tumor
Met diagnostic-positive status tested by immunohistochemistry (IHC)
Results of endothelial growth factor receptor (EGFR)-activating mutation testing
Radiographic evidence of disease
Prior treatment with at least one platinum-based line of treatment (for stage IIIb/IV) and no more than one additional line of chemotherapy treatment; the last dose of chemotherapy must have been administered >/= 21 days prior to Day 1
availability of tissue sample for diagnostic testing is required
Exclusion Criteria:
More than 30 days of exposure to an investigational or marketed agent that can act by EGFR inhibition, or a known EGFR-related toxicity resulting in dose modifications (EGFR inhibitors including but not limited to gefitinib, erlotinib and cetuximab)
Brain metastases or spinal cord compression not definitively treated with surgery and/or radiation, or previously treated central nervous system (CNS) metastases or spinal cord compression without evidence of stable disease for >/= 14 days
History of another malignancy in the previous 3 years, unless cured by surgery alone and continuously disease free for at least 3 years; participants with prior history of non-invasive cancers are eligible
Inadequate hematological, biochemical or organ function
Significant history of cardiac disease
Serious active infection at time of randomization or other serious underlying medical conditions that would impair the ability of the participant to receive protocol treatment
Any inflammatory changes of the surface of the eye
Clinically significant gastro-intestinal disease, including uncontrolled inflammatory gastro-intestinal diseases
Pregnant or lactating women
Positive for human immunodefinciency (HIV) infection
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ivor Caro, M.D.
Organizational Affiliation
Genentech, Inc.
Official's Role
Study Director
Facility Information:
City
Chandler
State/Province
Arizona
ZIP/Postal Code
85224
Country
United States
City
Hayward
State/Province
California
ZIP/Postal Code
94545
Country
United States
City
Modesto
State/Province
California
ZIP/Postal Code
95355
Country
United States
City
Oakland
State/Province
California
ZIP/Postal Code
94611
Country
United States
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
City
Roseville
State/Province
California
ZIP/Postal Code
95661
Country
United States
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
City
Sacramento
State/Province
California
ZIP/Postal Code
95825
Country
United States
City
San Diego
State/Province
California
ZIP/Postal Code
92108
Country
United States
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
City
San Jose
State/Province
California
ZIP/Postal Code
95119
Country
United States
City
Santa Clara
State/Province
California
ZIP/Postal Code
95051
Country
United States
City
South San Francisco
State/Province
California
ZIP/Postal Code
94080
Country
United States
City
Vallejo
State/Province
California
ZIP/Postal Code
94589
Country
United States
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94596
Country
United States
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33761
Country
United States
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33901
Country
United States
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32256
Country
United States
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
City
Urbana
State/Province
Illinois
ZIP/Postal Code
61801
Country
United States
City
Bettendorf
State/Province
Iowa
ZIP/Postal Code
52722
Country
United States
City
Sioux City
State/Province
Iowa
ZIP/Postal Code
51101
Country
United States
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
City
Annapolis
State/Province
Maryland
ZIP/Postal Code
21401
Country
United States
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21231
Country
United States
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21237
Country
United States
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
City
Springfield
State/Province
Massachusetts
ZIP/Postal Code
01107
Country
United States
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48106
Country
United States
City
Duluth
State/Province
Minnesota
ZIP/Postal Code
55805
Country
United States
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68114
Country
United States
City
Reno
State/Province
Nevada
ZIP/Postal Code
89502
Country
United States
City
Farmington
State/Province
New Mexico
ZIP/Postal Code
87401
Country
United States
City
Syracuse
State/Province
New York
ZIP/Postal Code
13210
Country
United States
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27514
Country
United States
City
Canton
State/Province
Ohio
ZIP/Postal Code
44718
Country
United States
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43219
Country
United States
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29403
Country
United States
City
Columbia
State/Province
South Carolina
ZIP/Postal Code
29210
Country
United States
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37404
Country
United States
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37909
Country
United States
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
City
Bristol
State/Province
Virginia
ZIP/Postal Code
24201
Country
United States
City
Roanoke
State/Province
Virginia
ZIP/Postal Code
24014
Country
United States
City
La Plata
ZIP/Postal Code
B1900BAJ
Country
Argentina
City
Quilmes
ZIP/Postal Code
1878
Country
Argentina
City
Santa Fe
ZIP/Postal Code
S3000FFU
Country
Argentina
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
City
Waratah
State/Province
New South Wales
ZIP/Postal Code
2298
Country
Australia
City
Chermside
State/Province
Queensland
ZIP/Postal Code
4032
Country
Australia
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5041
Country
Australia
City
Parkville
State/Province
Victoria
ZIP/Postal Code
3050
Country
Australia
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
City
Gent
ZIP/Postal Code
9000
Country
Belgium
City
Gilly (Charleroi)
ZIP/Postal Code
6000
Country
Belgium
City
Liège
ZIP/Postal Code
4000
Country
Belgium
City
Namur
ZIP/Postal Code
5000
Country
Belgium
City
Salvador/BA
State/Province
BA
ZIP/Postal Code
41820-021
Country
Brazil
City
Lajeado
State/Province
RS
ZIP/Postal Code
95900-000
Country
Brazil
City
Novo Hamburgo
State/Province
RS
ZIP/Postal Code
93510-250
Country
Brazil
City
Jau
State/Province
SP
ZIP/Postal Code
17210-080
Country
Brazil
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
08270-070
Country
Brazil
City
Sorocaba
State/Province
SP
ZIP/Postal Code
18030-005
Country
Brazil
City
Saint John
State/Province
New Brunswick
ZIP/Postal Code
E2L 4L2
Country
Canada
City
Sault Ste Marie
State/Province
Ontario
ZIP/Postal Code
P6A 2C4
Country
Canada
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3A 1A1
Country
Canada
City
Montreal
State/Province
Quebec
ZIP/Postal Code
J4B 5Z7
Country
Canada
City
Santiago
ZIP/Postal Code
0
Country
Chile
City
Santiago
ZIP/Postal Code
Providencia
Country
Chile
City
Temuco
ZIP/Postal Code
4810469
Country
Chile
City
Cakovec
ZIP/Postal Code
40000
Country
Croatia
City
Dubrovnik
ZIP/Postal Code
20000
Country
Croatia
City
Pula
ZIP/Postal Code
52100
Country
Croatia
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
City
Besancon
ZIP/Postal Code
25030
Country
France
City
Caen
ZIP/Postal Code
14076
Country
France
City
Grenoble
ZIP/Postal Code
38 043
Country
France
City
Limoges
ZIP/Postal Code
87042
Country
France
City
Marseille
ZIP/Postal Code
13915
Country
France
City
Montpellier
ZIP/Postal Code
34295
Country
France
City
Paris
ZIP/Postal Code
75970
Country
France
City
Poitiers
ZIP/Postal Code
86021
Country
France
City
Saint Herblain
ZIP/Postal Code
44805
Country
France
City
Suresnes
ZIP/Postal Code
92151
Country
France
City
Vandoeuvre-les-nancy
ZIP/Postal Code
54511
Country
France
City
Bad Berka
ZIP/Postal Code
99437
Country
Germany
City
Berlin
ZIP/Postal Code
14165
Country
Germany
City
Grosshansdorf
ZIP/Postal Code
22927
Country
Germany
City
Hamburg
ZIP/Postal Code
21075
Country
Germany
City
Heidelberg
ZIP/Postal Code
69126
Country
Germany
City
Karlsruhe
ZIP/Postal Code
76137
Country
Germany
City
Mainz
ZIP/Postal Code
55131
Country
Germany
City
München
ZIP/Postal Code
80336
Country
Germany
City
Oldenburg
ZIP/Postal Code
26121
Country
Germany
City
Regensburg
ZIP/Postal Code
93053
Country
Germany
City
Ulm
ZIP/Postal Code
89081
Country
Germany
City
Villingen-Schwenningen
ZIP/Postal Code
78052
Country
Germany
City
Pokfulam
Country
Hong Kong
City
Shatin
Country
Hong Kong
City
Edeleny
ZIP/Postal Code
3780
Country
Hungary
City
Miskolc
ZIP/Postal Code
3529
Country
Hungary
City
Szombathely
ZIP/Postal Code
9700
Country
Hungary
City
Cork
Country
Ireland
City
Dublin
ZIP/Postal Code
8
Country
Ireland
City
Beer Sheva
ZIP/Postal Code
8410101
Country
Israel
City
Haifa
ZIP/Postal Code
4959381
Country
Israel
City
Jerusalem
ZIP/Postal Code
91120-01
Country
Israel
City
Jerusalem
ZIP/Postal Code
9372212
Country
Israel
City
Kfar-Saba
ZIP/Postal Code
4428164
Country
Israel
City
Petach Tikva
ZIP/Postal Code
49100
Country
Israel
City
Ramat Gan
ZIP/Postal Code
5262100
Country
Israel
City
Rehovot
ZIP/Postal Code
76100
Country
Israel
City
Aviano
State/Province
Friuli-Venezia Giulia
ZIP/Postal Code
33081
Country
Italy
City
Genova
State/Province
Liguria
ZIP/Postal Code
16132
Country
Italy
City
Milan
State/Province
Lombardia
ZIP/Postal Code
20141
Country
Italy
City
Monza
State/Province
Lombardia
ZIP/Postal Code
20900
Country
Italy
City
Rozzano
State/Province
Lombardia
ZIP/Postal Code
20089
Country
Italy
City
Ancona
State/Province
Marche
ZIP/Postal Code
60121
Country
Italy
City
Orbassano
State/Province
Piemonte
ZIP/Postal Code
10043
Country
Italy
City
Lido Di Camaiore
State/Province
Toscana
ZIP/Postal Code
55043
Country
Italy
City
Perugia
State/Province
Umbria
ZIP/Postal Code
06123
Country
Italy
City
Aichi
ZIP/Postal Code
464-8681
Country
Japan
City
Chiba
ZIP/Postal Code
277-8577
Country
Japan
City
Ehime
ZIP/Postal Code
791-0280
Country
Japan
City
Fukuoka
ZIP/Postal Code
811-1395
Country
Japan
City
Fukuoka
ZIP/Postal Code
812-8582
Country
Japan
City
Hyogo
ZIP/Postal Code
650-0047
Country
Japan
City
Hyogo
ZIP/Postal Code
673-8553
Country
Japan
City
Kanagawa
ZIP/Postal Code
236-0051
Country
Japan
City
Kyoto
ZIP/Postal Code
606-8507
Country
Japan
City
Miyagi
ZIP/Postal Code
980-8574
Country
Japan
City
Miyagi
ZIP/Postal Code
981-1293
Country
Japan
City
Okayama
ZIP/Postal Code
700-8558
Country
Japan
City
Okayama
ZIP/Postal Code
710-8602
Country
Japan
City
Osaka
ZIP/Postal Code
534-0021
Country
Japan
City
Osaka
ZIP/Postal Code
537-8511
Country
Japan
City
Osaka
ZIP/Postal Code
589-8511
Country
Japan
City
Osaka
ZIP/Postal Code
591-8555
Country
Japan
City
Saitama
ZIP/Postal Code
362-0806
Country
Japan
City
Shizuoka
ZIP/Postal Code
411-8777
Country
Japan
City
Tokyo
ZIP/Postal Code
104-0045
Country
Japan
City
Tokyo
ZIP/Postal Code
113-8677
Country
Japan
City
Tokyo
ZIP/Postal Code
135-8550
Country
Japan
City
Tokyo
ZIP/Postal Code
160-0023
Country
Japan
City
Tokyo
ZIP/Postal Code
173-8605
Country
Japan
City
Yamaguchi
ZIP/Postal Code
755-0241
Country
Japan
City
Gyeonggi-do
ZIP/Postal Code
443-380
Country
Korea, Republic of
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
City
Seoul
ZIP/Postal Code
06591
Country
Korea, Republic of
City
Seoul
ZIP/Postal Code
120-752
Country
Korea, Republic of
City
Amsterdam
ZIP/Postal Code
1081 HV
Country
Netherlands
City
Groningen
ZIP/Postal Code
9700 RB
Country
Netherlands
City
Maastricht
ZIP/Postal Code
6229 HX
Country
Netherlands
City
Lima
ZIP/Postal Code
L27
Country
Peru
City
Lima
ZIP/Postal Code
Lima 1
Country
Peru
City
Lima
ZIP/Postal Code
Lima 27
Country
Peru
City
Gdansk
ZIP/Postal Code
80-952
Country
Poland
City
Krakow
ZIP/Postal Code
31-531
Country
Poland
City
Lodz
ZIP/Postal Code
93-509
Country
Poland
City
Olsztyn
ZIP/Postal Code
10-357
Country
Poland
City
Poznan
Country
Poland
City
Ivanovo
ZIP/Postal Code
153040
Country
Russian Federation
City
Krasnodar
ZIP/Postal Code
350040
Country
Russian Federation
City
Omsk
ZIP/Postal Code
644013
Country
Russian Federation
City
Saint-Petersburg
ZIP/Postal Code
197101
Country
Russian Federation
City
St. Petersburg
ZIP/Postal Code
189646
Country
Russian Federation
City
St. Petersburg
ZIP/Postal Code
197022
Country
Russian Federation
City
Tomsk
ZIP/Postal Code
634050
Country
Russian Federation
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
City
Belgrade
ZIP/Postal Code
11080
Country
Serbia
City
Kragujevac
ZIP/Postal Code
34000
Country
Serbia
City
Bloemfontein
ZIP/Postal Code
9301
Country
South Africa
City
Johannesburg
ZIP/Postal Code
2193
Country
South Africa
City
Sandton
ZIP/Postal Code
2196
Country
South Africa
City
Sabadell
State/Province
Barcelona
ZIP/Postal Code
08208
Country
Spain
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
City
Barcelona
ZIP/Postal Code
08916
Country
Spain
City
Madrid
ZIP/Postal Code
28007
Country
Spain
City
Madrid
ZIP/Postal Code
28034
Country
Spain
City
Madrid
ZIP/Postal Code
28050
Country
Spain
City
Madrid
ZIP/Postal Code
28222
Country
Spain
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
City
Valencia
ZIP/Postal Code
41014
Country
Spain
City
Changhua
ZIP/Postal Code
500
Country
Taiwan
City
Kaohsiung
ZIP/Postal Code
813
Country
Taiwan
City
Taipei
ZIP/Postal Code
100
Country
Taiwan
City
Cherkassy
ZIP/Postal Code
18009
Country
Ukraine
City
Chernivtsi
ZIP/Postal Code
58013
Country
Ukraine
City
Dnipropetrovsk
ZIP/Postal Code
49102
Country
Ukraine
City
Sumy
ZIP/Postal Code
40005
Country
Ukraine
City
Zaporizhzhya
ZIP/Postal Code
69040
Country
Ukraine
City
Belfast
ZIP/Postal Code
BT9 7AB
Country
United Kingdom
City
Grimsby
ZIP/Postal Code
DN33 2BA
Country
United Kingdom
City
Leicester
ZIP/Postal Code
LE1 5WW
Country
United Kingdom
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
City
London
ZIP/Postal Code
SW10 9NH
Country
United Kingdom
City
Manchester
ZIP/Postal Code
M2O 4BX
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
24687921
Citation
Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, Raja R, Mohan S, Patel R, Desai R, Fu L, Do A, Parab V, Xia X, Januario T, Louie SG, Filvaroff E, Shames DS, Wistuba I, Lipkind M, Huang J, Lazarov M, Ramakrishnan V, Amler L, Phan SC, Patel P, Peterson A, Yauch RL. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib+/-onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res. 2014 Sep 1;20(17):4488-98. doi: 10.1158/1078-0432.CCR-13-1836. Epub 2014 Mar 31.
Results Reference
derived
Learn more about this trial
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
We'll reach out to this number within 24 hrs